Zooming in on breast cancer reveals how mutations shape the tumour landscape

(Cancer Research UK) Scientists have created one of the most detailed maps of breast cancer ever achieved, revealing how genetic changes shape the physical tumour landscape, according to research funded by Cancer Research UK and published in Nature Cancer today (Monday). An international team of scientists has developed intricate maps of breast tumour samples, with a resolution smaller than a single cell.
Source: EurekAlert! - Biology - Category: Biology Source Type: news

Related Links:

OBJECTIVES: Aromatase inhibitors are the first-choice drugs for the treatment of hormone sensitive breast cancer. However, in addition to the scarcity of studies, there are controversies about their effects on vaginal epithelial cell proliferation in rats, especially those in persistent estrus. METHODS: To investigate vaginal epithelial cell proliferation by Ki-67 antigen expression, persistent estrus was induced in 42 randomly selected rats. These rats were randomly divided into 2 groups: group I (control, n=21), which received 0.1 mL of propylene glycol (vehicle) daily, and group II (experimental, n=21), which received 0...
Source: Clinics - Category: General Medicine Source Type: research
17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells. Oncol Rep. 2020 Mar 26;: Authors: Zuo Y, Xu H, Chen Z, Xiong F, Zhang B, Chen K, Jiang H, Luo C, Zhang H Abstract Breast cancer is one of the most common malignancies that threaten the health of women. Although there are a few chemotherapies for the clinical treatment of breast cancer, these therapies are faced with the problems of drug‑resistance and metastasis. Drug combination can help to reduce the adverse side effects of chemotherapies using single drugs, and ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
In conclusion, sHER2‑ECD and tissue calpain‑10 may be used as new prognostic indices for breast cancer. PMID: 32236617 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Gao X, Bao H, Liu L, Zhu W, Zhang L, Yue L Abstract Abnormal protein acetylation and succinylation in lysine residues can cause the initiation and development of numerous different types of tumors. However, to the best of our knowledge, there is currently a lack of systematic investigation in breast cancer. Using proteomic techniques, the present study systematically investigated the two modifications of all proteins in invasive ductal carcinoma tissues to identify potential targets. The results revealed significantly higher modification levels for the majority of proteins in breast cancer tissue when comp...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Cannabidiolic acid dampens the expression of cyclooxygenase-2 in MDA-MB-231 breast cancer cells: Possible implication of the peroxisome proliferator-activated receptor β/δ abrogation. J Toxicol Sci. 2020;45(4):227-236 Authors: Hirao-Suzuki M, Takeda S, Koga T, Takiguchi M, Toda A Abstract A growing body of experimental evidence strongly suggests that cannabidiolic acid (CBDA), a major component of the fiber-type cannabis plant, exerts a variety of biological activities. We have reported that CBDA can abrogate cyclooxygenase-2 (COX-2) expression and its enzymatic activity. It is established t...
Source: Journal of Toxicological Sciences - Category: Toxicology Tags: J Toxicol Sci Source Type: research
Dalton Trans., 2020, Advance Article DOI: 10.1039/D0DT00507J, CommunicationYi Dai, Hai Huang, Yang Zhu, Junjie Cheng, Ai-Zong Shen, Yangzhong Liu Pt-ATRA, a carboplatin analogue containing an all-trans retinoic acid (ATRA) derivative ligand, was synthesizedvia a click reaction. Pt-ATRA demonstrates dual function by inducing cell apoptosis and inhibiting tumor metastasis. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Dalton Trans. latest articles - Category: Chemistry Authors: Source Type: research
Abstract Breast cancer is the most frequent in women, resulting in fatigue and depressive symptoms as consequence of treatment, but physical activity can help in this process. The aim of this study was to investigate the relationship between fatigue, depressive symptoms and practice of physical activity of women with breast cancer during treatment or after cancer treatment. This is a cross-sectional study with 179 women (56.89 ± 9.4 years) from the Oncology Research Center - CEPON, using questionnaire on general and clinical information, fatigue (Piper Fatigue Scale) depressive symptoms (Beck Depression Inventory) a...
Source: Revista Brasileira de Cineantropometria e Desempenho Humano - Category: Sports Medicine Source Type: research
Authors: Montemurro F, Nuzzolese I, Ponzone R Abstract Introduction: The administration of chemotherapy before (neoadjuvant), rather than after surgery (adjuvant) in early breast cancer has been considered an optional strategy for patients with operable breast cancer. We reviewed this concept considering recent results in the field.Areas covered: Herein, the authors cover neoadjuvant chemotherapy with or without biologics in triple-negative and HER2-positive operable breast cancer with a focus on rates of complete pathological remission (pCR) in the breast and axilla. The impact of the CREATE X and KATERINE randomi...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Publication date: Available online 2 April 2020Source: Saudi Pharmaceutical JournalAuthor(s): Md. Salman Akhtar, Naseem Akhter, Mohammad Zeeshan Najm, SVS Deo, NK Shukla, Shaia Saleh R. Almalki, Raed A. Alharbi, Abdulmajeed Abdulghani A. Sindi, Abdulmohsen Alruwetei, Abrar Ahmad, Syed Akhtar Husain
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Conditions:   Breast;   Metastatic;   Triple Negative;   Cancer;   Disseminated Tumor Cell Interventions:   Drug: Capecitabine;   Combination Product: Sarilumab 150mg or 200 mg plus Capecitabine;   Combination Product: Sarilumab 150mg plus Capecitabine Sponsors:   University of Florida;   National Institutes of Health (NIH) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biology | Breast Cancer | Cancer | Cancer & Oncology | Genetics